Research map: Beyond androgen deprivation therapy: Next-generation hormonal therapies and emerging combination approaches in advanced prostate cancer

Back to the article

Papers in this map

  1. The nuclear receptor superfamily: The second decade · David J. Mangelsdorf · 1995 · 7019 citations · Cited by this paper
  2. Systemic therapies in prostate cancer: A field in transformation · Clara Hwang · 2026 · Cites this paper
  3. Does size matter? A national analysis of patterns of adjuvant immunotherapy receipt and tumor size–dependent survival in pT3N0M0 clear cell renal cell carcinoma · 2026 · Related
  4. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy · Howard I. Scher · 2012 · 4644 citations · Cited by this paper
  5. Association of time to upfront treatment initiation with outcomes in metastatic hormone-sensitive prostate cancer: a 4-month landmark analysis · Eisuke Iwaori · 2026 · Cites this paper
  6. Sex-based differences in peri-operative and long-term oncologic outcomes after primary surgical treatment for kidney cancer: A comprehensive analysis from a high-volume tertiary center · 2026 · Related
  7. Abiraterone and Increased Survival in Metastatic Prostate Cancer · Johann Sebastian De Bono · 2011 · 4445 citations · Cited by this paper
  8. Universally offered germline testing in upper tract urothelial carcinoma · 2026 · Related
  9. Integrative Clinical Genomics of Advanced Prostate Cancer · Dan R. Robinson · 2015 · 3730 citations · Cited by this paper
  10. Automated algorithm for surgical outcomes abstraction for cystectomy · 2026 · Related
  11. Olaparib for Metastatic Castration-Resistant Prostate Cancer · Johann Sebastian De Bono · 2020 · 2327 citations · Cited by this paper
  12. Post-treatment diffusion MRI–derived apparent diffusion coefficient as a biomarker of response and prognosis following definitive radiotherapy for prostate cancer: Impact of focal dose escalation on ADC dynamics · 2026 · Related
  13. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer · Karim S. Fizazi · 2017 · 2313 citations · Cited by this paper
  14. Beyond PSA90: Deep PSA response predicts outcomes in nonmetastatic CRPC · 2026 · Related
  15. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer · Ian D. Davis · 2019 · 1651 citations · Cited by this paper
  16. Clinical outcomes of deferred cytoreductive nephrectomy after initial systemic therapy in metastatic renal cell carcinoma: A multicenter retrospective study · 2026 · Related
  17. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer · Kim N. Chi · 2019 · 1577 citations · Cited by this paper
  18. Association of EVITA with safety in advanced urothelial carcinoma: A multicenter real-world study · 2026 · Related
  19. Induced protein degradation: an emerging drug discovery paradigm · Ashton C. Lai · 2016 · 1466 citations · Cited by this paper
  20. Featured SUO Fellow: Parth Thakker, MD · 2026 · Related
  21. Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth · Bruce Montgomery · 2008 · 1428 citations · Cited by this paper
  22. Identification and validation of TP53/p53 status as a prognostic marker in penile squamous cell carcinoma: Evidence from a cohort study and meta-analysis · 2026 · Related
  23. Structural basis of PROTAC cooperative recognition for selective protein degradation · Morgan S. Gadd · 2017 · 1248 citations · Cited by this paper
  24. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer · Irfan Ahmed Asangani · 2014 · 965 citations · Cited by this paper
  25. Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven · Gerhardt Attard · 2008 · 903 citations · Cited by this paper
  26. The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings · Thomas Helleday · 2011 · 869 citations · Cited by this paper
  27. Clinical implications of PTEN loss in prostate cancer · Tamara Jamaspishvili · 2018 · 678 citations · Cited by this paper
  28. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements · Michael C. Haffner · 2010 · 624 citations · Cited by this paper
  29. N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer · Étienne Dardenne · 2016 · 588 citations · Cited by this paper
  30. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial · Neeraj Agarwal · 2023 · 535 citations · Cited by this paper
  31. Selective Retention of Dihydrotestosterone by Prostatic Nuclei · Ken M. Anderson · 1968 · 534 citations · Cited by this paper
  32. Phosphorylation‐dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase · Hui-Kuan Lin · 2002 · 459 citations · Cited by this paper
  33. Dual Roles of PARP-1 Promote Cancer Growth and Progression · Matthew Joseph Schiewer · 2012 · 453 citations · Cited by this paper
  34. Rucaparib or Physician’s Choice in Metastatic Prostate Cancer · Karim S. Fizazi · 2023 · 450 citations · Cited by this paper
  35. Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer · Noel William Clarke · 2022 · 425 citations · Cited by this paper
  36. The Intranuclear Binding of Testosterone and 5α-Androstan-17β-ol-3-one by Rat Prostate · Nicholas Bruchovsky · 1968 · 405 citations · Cited by this paper
  37. Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance · Jemilat Salami · 2018 · 354 citations · Cited by this paper
  38. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer · Kim N. Chi · 2023 · 349 citations · Cited by this paper
  39. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial · Christopher J. Sweeney · 2021 · 340 citations · Cited by this paper

Source: OpenAlex (CC0)